{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T14:55:47Z","timestamp":1791471347051,"version":"4.3.4"},"reference-count":37,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Obesity Research & Clinical Practice"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.orcp.2026.09.001","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:07:01Z","timestamp":1789506421000},"page":"437-444","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A multicenter real-world study on the safety and effectiveness of the glucagon-like peptide-1 receptor agonist (liraglutide) in adolescents with obesity in Taiwan"],"prefix":"10.1016","volume":"20","author":[{"given":"Chiao-Fan","family":"Chiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chu-Kuang","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Wei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuo-Chin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Lei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiang-Fan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang-Lin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4074-5838","authenticated-orcid":false,"given":"Huey-Ling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8582-927X","authenticated-orcid":false,"given":"Chun-Yan","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10431","key":"10.1016\/j.orcp.2026.09.001_bib1","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S0140-6736(23)02750-2","article-title":"Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults","volume":"403","author":"Phelps","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.orcp.2026.09.001_bib2","unstructured":"Taiwan Health Promotion Administration, Taiwan Pediatric Association. Evidences-based Guideline on Children Obesity Prevention and Management. Publication in Chinese. 2018. https:\/\/www.hpa.gov.tw\/Pages\/EBook.aspx?nodeid=3792."},{"key":"10.1016\/j.orcp.2026.09.001_bib3","unstructured":"World Health Organization. Growth reference data for 5-19 years. 2007."},{"issue":"2","key":"10.1016\/j.orcp.2026.09.001_bib4","article-title":"Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity","volume":"151","author":"Hampl","year":"2023","journal-title":"Pediatrics"},{"issue":"23","key":"10.1016\/j.orcp.2026.09.001_bib5","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1001\/jama.2017.6803","article-title":"Screening for obesity in children and adolescents: US Preventive Services Task Force recommendation statement","volume":"317","author":"Grossman","year":"2017","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.orcp.2026.09.001_bib6","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.2337\/dc24-1236","article-title":"Steatotic Liver Disease in Pediatric Obesity and Increased Risk for Youth-Onset Type 2 Diabetes","volume":"47","author":"Putri","year":"2024","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.orcp.2026.09.001_bib7","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1001\/jama.2024.11146","article-title":"Interventions for High Body Mass Index in Children and Adolescents","volume":"332","author":"Nicholson","year":"2024","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.orcp.2026.09.001_bib8","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1001\/jama.2024.11809","article-title":"Obesity in Adolescents: A Review","volume":"332","author":"Kelly","year":"2024","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.orcp.2026.09.001_bib9","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"issue":"9","key":"10.1016\/j.orcp.2026.09.001_bib10","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.2337\/diab.44.9.1126","article-title":"Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects","volume":"44","author":"Deacon","year":"1995","journal-title":"Diabetes"},{"key":"10.1016\/j.orcp.2026.09.001_bib11","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3389\/fendo.2019.00155","article-title":"The discovery and development of liraglutide and semaglutide","volume":"10","author":"Knudsen","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"12","key":"10.1016\/j.orcp.2026.09.001_bib12","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/j.1463-1326.2009.01158.x","article-title":"Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue","volume":"11","author":"Jendle","year":"2009","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.orcp.2026.09.001_bib13","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s40262-015-0343-6","article-title":"Liraglutide in type 2 diabetes mellitus: clinical pharmacokinetics and pharmacodynamics","volume":"55","author":"Jacobsen","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.orcp.2026.09.001_bib14","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s12325-010-0110-x","article-title":"The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients","volume":"28","author":"Flint","year":"2011","journal-title":"Adv Ther"},{"issue":"1","key":"10.1016\/j.orcp.2026.09.001_bib15","article-title":"Effects of GLP-1 and incretin-based therapies on gastrointestinal motor function","volume":"2011","author":"Marathe","year":"2011","journal-title":"J Diabetes Res"},{"issue":"1","key":"10.1016\/j.orcp.2026.09.001_bib16","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1463-1326.2012.01673.x","article-title":"Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme","volume":"15","author":"Niswender","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.orcp.2026.09.001_bib17","unstructured":"Novo Nordisk. Saxenda [package insert]. 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/206321orig1s000lbl.pdf."},{"key":"10.1016\/j.orcp.2026.09.001_bib18","unstructured":"Novo Nordisk. Saxenda solution for injection [package insert]. Taiwan Food and Drug Administration; 2020."},{"issue":"22","key":"10.1016\/j.orcp.2026.09.001_bib19","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1916038","article-title":"A randomized, controlled trial of liraglutide for adolescents with obesity","volume":"382","author":"Kelly","year":"2020","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.orcp.2026.09.001_bib20","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","year":"2013","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.orcp.2026.09.001_bib21","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/pds.1471","article-title":"Guidelines for good pharmacoepidemiology practices (GPP)","volume":"17","author":"International Society of Pharmacoepidemiology (ISPE)","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"9","key":"10.1016\/j.orcp.2026.09.001_bib22","doi-asserted-by":"crossref","first-page":"660","DOI":"10.2471\/BLT.07.043497","article-title":"Development of a WHO growth reference for school-aged children and adolescents","volume":"85","author":"Onis","year":"2007","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.orcp.2026.09.001_bib23","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jpeds.2016.10.076","article-title":"Liraglutide in an Adolescent Population with Obesity: A Randomized, Double-Blind, Placebo-Controlled 5-Week Trial to Assess Safety, Tolerability, and Pharmacokinetics of Liraglutide in Adolescents Aged 12-17 Years","volume":"181","author":"Danne","year":"2017","journal-title":"J Pediatr"},{"issue":"5","key":"10.1016\/j.orcp.2026.09.001_bib24","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/dom.12639","article-title":"Exposure\u2013response analyses of liraglutide 3.0\u2009mg for weight management","volume":"18","author":"Wilding","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"10.1016\/j.orcp.2026.09.001_bib25","doi-asserted-by":"crossref","DOI":"10.1111\/ijpo.12799","article-title":"Liraglutide pharmacokinetics and exposure-response in adolescents with obesity","volume":"16","author":"Carlsson Petri","year":"2021","journal-title":"Pediatr Obes"},{"issue":"3","key":"10.1016\/j.orcp.2026.09.001_bib26","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2017-1904","article-title":"Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents","volume":"140","author":"Flynn","year":"2017","journal-title":"Pediatrics"},{"key":"10.1016\/j.orcp.2026.09.001_bib27","first-page":"1","article-title":"Long-term administration of liraglutide for weight management in pediatric patients under 18 years: evidence from 7 randomized controlled trials","author":"Dong","year":"2025","journal-title":"Pediatr Res"},{"issue":"2","key":"10.1016\/j.orcp.2026.09.001_bib28","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s11901-014-0227-5","article-title":"Hepatic Steatosis and Steatohepatitis: Are they Really Two Distinct Entities?","volume":"13","author":"Fielding","year":"2014","journal-title":"Curr Hepatol Rep"},{"issue":"6","key":"10.1016\/j.orcp.2026.09.001_bib29","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1002\/hep.22858","article-title":"Glucose dysregulation and hepatic steatosis in obese adolescents: is there a link?","volume":"49","author":"Cali","year":"2009","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.orcp.2026.09.001_bib30","doi-asserted-by":"crossref","first-page":"905","DOI":"10.2337\/dc11-1754","article-title":"Metabolic consequences of hepatic steatosis in overweight and obese adolescents","volume":"35","author":"Wicklow","year":"2012","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.orcp.2026.09.001_bib31","doi-asserted-by":"crossref","DOI":"10.1002\/jgh3.70137","article-title":"Consensus Statement on Metabolic Dysfunction-Associated Steatotic Liver Disease in Children and Adolescents From the Joint TASL-TSPGHAN Expert Committee","volume":"9","author":"Lin","year":"2025","journal-title":"JGH Open"},{"issue":"10019","key":"10.1016\/j.orcp.2026.09.001_bib32","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.orcp.2026.09.001_bib33","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.orcp.2026.09.001_bib34","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 Trial of Semaglutide in Metabolic Dysfunction\u2013Associated Steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.orcp.2026.09.001_bib35","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3390\/children11030275","article-title":"Glucagon-like Peptide-1 Receptor Agonists\u2014A Potential New Medication for Pediatric Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD)","volume":"11","author":"Choi","year":"2024","journal-title":"Children"},{"issue":"3","key":"10.1016\/j.orcp.2026.09.001_bib36","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/osp4.328","article-title":"Efficacy and safety of liraglutide in Indian adolescents with obesity","volume":"5","author":"Kochar","year":"2019","journal-title":"Obes Sci Pract"},{"issue":"1","key":"10.1016\/j.orcp.2026.09.001_bib37","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jfma.2021.01.004","article-title":"Predictors for incidence and remission of nonalcoholic fatty liver disease in obese children and adolescents","volume":"121","author":"Lin","year":"2022","journal-title":"J Formos Med Assoc"}],"container-title":["Obesity Research & Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871403X26000852?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871403X26000852?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T14:19:37Z","timestamp":1791469177000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871403X26000852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1871403X26000852"],"URL":"https:\/\/doi.org\/10.1016\/j.orcp.2026.09.001","relation":{},"ISSN":["1871-403X"],"issn-type":[{"value":"1871-403X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A multicenter real-world study on the safety and effectiveness of the glucagon-like peptide-1 receptor agonist (liraglutide) in adolescents with obesity in Taiwan","name":"articletitle","label":"Article Title"},{"value":"Obesity Research & Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.orcp.2026.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of Asia Oceania Association for the Study of Obesity.","name":"copyright","label":"Copyright"}]}}